CDC Claims On Vaccination And Natural Immunity Made Without Seeing Underlying Data: FOIA Document
Authored by Hans Mahncke via The Epoch Times (emphasis ours), In a new Freedom of Information Act (FOIA) response, the Centers for Disease Control and Prevention (CDC) now admits that it recommended…#cdc #foiadocumentauthored #hansmahncke #epochtimes #foia #atlanta #ericbaradatafp #pfizer #astrazeneca #merck (Source: Reuters: Health)
Source: Reuters: Health - November 18, 2023 Category: Consumer Health News Source Type: news
FDA Approves Truqap (capivasertib) plus Faslodex for Patients with Advanced HR-Positive Breast Cancer
17 November 2023 -- AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 17, 2023 Category: Drugs & Pharmacology Source Type: news
AstraZeneca Pharma India plans to sell Bengaluru plant
The company will position the manufacturing site for sale in a fully operational manner and begin a search for a buyer who can also act as a contract manufacturing organisation (CMO) for its products currently manufactured or packaged at the site, subject to receipt of necessary statutory approvals, the drug firm said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 16, 2023 Category: Pharmaceuticals Source Type: news
AstraZeneca Targets New Pill as Cheaper Option for Losing a ‘Bit of Weight’
The U.K.-based drugmaker AstraZeneca is jumping into the increasingly crowded race to bring an effective weight-loss pill to market, and it says its late start won’t be a major setback.#astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2023 Category: Consumer Health News Source Type: news
David Cameron ’s return brings his role for fallen Greensill back to the fore
The surprise return of former Prime Minister David Cameron as the U.K.’s new foreign secretary brings his work for the fallen Greensill Capital back to the limelight. Greensill Capital was a company run by financier Lex Greensill that provided supply-chain financing. Supply-chain financing is…#davidcameron #greensillcapital #lexgreensill #fordmotorco #astrazeneca #sanjeevgupta #ukseriousfraudoffice #greensill #ubs #treasury (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2023 Category: Consumer Health News Source Type: news
Certain COVID-19 Vaccines Linked To Elevated Risk Of Guillain-Barr é Syndrome
Certain COVID-19 Vaccines Linked To Elevated Risk Of Guillain-Barré Syndrome Authored by Ellen Wan via The Epoch Times (emphasis ours), As the vaccination rate continues to rise, an increasing number of side effects are being reported. Research indicates that COVID-19 viral vector-based vaccines…#vaccineslinked #ellenwan #epochtimes #gbs #astrazeneca #scientificreports #gyeonggiprovince #pfizer #moderna #malta (Source: Reuters: Health)
Source: Reuters: Health - November 12, 2023 Category: Consumer Health News Source Type: news
AstraZeneca adds to obesity drug race, but Eli Lilly remains in lead
remains our favorite way to play the weight-loss drug market, despite a new entry this week from AstraZeneca (AZN). On Thursday, AstraZeneca said it paid $185 million upfront to acquire the rights to an experimental weight-loss pill from Eccogene, a Chinese biotech startup. AstraZeneca hopes to…#astrazeneca #azn #elililly #jimcramer #danish #novonordisk #nvo #club #zepbound #novoozempic (Source: Reuters: Health)
Source: Reuters: Health - November 10, 2023 Category: Consumer Health News Source Type: news
'Words were my life but now they're gone': Actress, 42, left unable to perform after suffering stroke triggered by AstraZeneca Covid jab
In February 2020, Australin actor Melle Stewart was enjoying standing ovations in Belfast. But she is now unable to walk or talk following a devastating complication from an AstraZeneca Covid jab. (Source: the Mail online | Health)
Source: the Mail online | Health - November 10, 2023 Category: Consumer Health News Source Type: news
AstraZeneca announces new anti-obesity drug deal and positive profit
AstraZeneca's share price climbed on Thursday after it announced a multi-billion dollar deal with Chinese biopharmaceutical company Eccogene to produce a new anti-diabetes and obesity drug. In an investor update, the multinational pharmaceutical group also posted total revenue of $33.8bn for the…#astrazeneca #anglo #q3 #coreeps #pascalsoriot (Source: Reuters: Health)
Source: Reuters: Health - November 10, 2023 Category: Consumer Health News Source Type: news
AstraZeneca faces legal challenge over Covid vaccine
Claimant Jamie Scott suffered suffered severe brain injury after having the Covid jab in April 2021. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 9, 2023 Category: Consumer Health News Source Type: news
The $2 Billion Bet AstraZeneca Is Making In Weight Loss
Shares of AZN stock popped Thursday after AstraZeneca (AZN) said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene. The news comes a day after Eli Lilly (LLY) gained U.S. approval for Zepbound, a rival to Novo Nordisk's (NVO) Wegovy. Both drugs target a…#azn #astrazeneca #elililly #lly #novonordisk #glp1 #allisongatlin #twitter #ibdagatlin #lookingfornextapple (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2023 Category: Consumer Health News Source Type: news
AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs
Shares of AZN stock popped Thursday after AstraZeneca said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene. The post AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs appeared first on Investor's Business Daily.#azn #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2023 Category: Consumer Health News Source Type: news
AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill
AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight-loss and diabetes drugs Ozempic and Wegovy. AstraZeneca said Thursday it had reached an exclusive license…#astrazeneca #ecc5004 #glp1 #pascalsoriot #ozempic #wegovyormounjaro #novonordisk #wegovyandozempic #novonordisks #fda (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2023 Category: Consumer Health News Source Type: news
How safe is AstraZeneca's Covid jab? What rare complications can it cause? Who is taking legal action against the pharma giant? All you need to know
As Brits take AstraZeneca to court over deaths and injuries linked to its Covid jab we answer all your questions about the vaccine, the risks, and who could end up paying for compensation. (Source: the Mail online | Health)
Source: the Mail online | Health - November 9, 2023 Category: Consumer Health News Source Type: news
AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill —As Weight Loss Drug Market Grows
The drug is similar to Ozempic, which is commonly used for diabetes and weight loss. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 9, 2023 Category: Pharmaceuticals Authors: Ty Roush, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news
